Pharmacokinetic and pharmacodynamic assessment of alirocumab in patients with familial hypercholesterolemia associated with proprotein convertase subtilisin/kexin type 9 gain-of-function or apolipoprotein B loss-of-function mutations - Sorbonne Université
Journal Articles Journal of clinical lipidology Year : 2019

Pharmacokinetic and pharmacodynamic assessment of alirocumab in patients with familial hypercholesterolemia associated with proprotein convertase subtilisin/kexin type 9 gain-of-function or apolipoprotein B loss-of-function mutations

Domains

Life Sciences [q-bio]

Maryse Guerin  : Connect in order to contact the contributor

https://hal.sorbonne-universite.fr/hal-03970307

Submitted on : Thursday, February 2, 2023-4:34:28 PM

Last modification on : Thursday, December 14, 2023-1:50:38 PM

Consult the full text

Dates and versions

hal-03970307 , version 1 (02-02-2023)

Identifiers

Cite

Paul Hopkins, Michel Krempf, Eric Bruckert, Stephen Donahue, Feng Yang, et al.. Pharmacokinetic and pharmacodynamic assessment of alirocumab in patients with familial hypercholesterolemia associated with proprotein convertase subtilisin/kexin type 9 gain-of-function or apolipoprotein B loss-of-function mutations. Journal of clinical lipidology, 2019, 13 (6), pp.970-978. ⟨10.1016/j.jacl.2019.10.007⟩. ⟨hal-03970307⟩

Export

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

ICAN SORBONNE-UNIVERSITE SU-MEDECINE IHU_ICAN
9 View
0 Download

Altmetric

Share

More